Opinion|Videos|September 23, 2024
Advanced HCC: Key Takeaways
Key opinion leaders summarize essential takeaways and highlight unmet needs in the hepatocellular carcinoma treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some key takeaways from this analysis?
- What are some clinical pearls you wish to offer your community colleagues who are considering treating their patients with atezo + bev? (EGD consideration, etc)
- What are some unmet needs in the treatment of advanced HCC?
Advertisement
Related to this article
Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.
![“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg?w=350&fit=crop&auto=format)
“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
2
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
3
FDA OKs Pirtobrutinib in Frontline CLL/SLL
4
How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?
5